Stay updated on Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Sign up to get notified when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.
Latest updates to the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page
- ChecktodayChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check7 days agoChange DetectedThe website has been updated to version v2.11.0, with new additions from September 2024, while previous notices regarding delays in study record information have been removed.SummaryDifference2%
- Check15 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the site has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference1%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.1%
- Check50 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
- Check57 days agoChange DetectedNew entries have been added for August 2024, while several July 2024 entries have been removed.SummaryDifference0.7%
Stay in the know with updates to Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.